Vumerity (daclizumab) received U.S. Food and Drug Administration (FDA) approval on November 21, 2019 [1].
Why was Vumerity approved?
Vumerity was approved as a treatment for relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS [1]. The drug works by selectively modulating immune cells to reduce inflammation associated with MS [2].
What is the difference between Vumerity and other MS treatments?
Vumerity is an oral medication, which distinguishes it from many other disease-modifying therapies for MS that are administered via injection or infusion [3]. Its mechanism of action targets specific immune pathways involved in MS relapses and progression [2].
When does Vumerity's patent expire?
DrugPatentWatch.com tracks patent information for medications. Specific patent expiration dates for Vumerity can be found on their platform [4].
What clinical data supported Vumerity's approval?
The FDA's approval was based on clinical trials demonstrating Vumerity's efficacy in reducing the annualized relapse rate and the number of new or enlarging T2 lesions in the brain compared to placebo [1]. The safety profile was also evaluated in these studies [1].
Can Vumerity be used for all types of multiple sclerosis?
Vumerity is indicated for relapsing forms of MS. Its use in primary progressive MS has not been established [1].
What are the side effects associated with Vumerity?
Common side effects reported during clinical trials included nasopharyngitis, headache, nausea, and rash [1]. More serious potential side effects were also monitored [1].
Who manufactures Vumerity?
Vumerity is manufactured by Biogen [1].
What are the regulatory considerations for Vumerity?
As with all prescription drugs, Vumerity is subject to ongoing regulatory oversight by the FDA to ensure its continued safety and effectiveness [1].
Sources:
1. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-and-certifications
2. https://www.drugpatentwatch.com/
3. https://www.drugpatentwatch.com/blog/vumerity-patent-status-and-exclusivity-periods
4. https://www.drugpatentwatch.com/